Ocaratuzumab

Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) [1][2].

Product Specifications

CAS Number

[1169956-08-4]

Product Name Alternative

AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ocaratuzumab.html

Purity

95.00

Solubility

H2O

Smiles

[Ocaratuzumab]

Molecular Weight

(145.38 kDa)

References & Citations

[1]Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18 (5) :1395-403.|[2]Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6 (3) :749-55.